Abstract P1-09-02: Health Care Costs Incurred by Post-Menopausal Women with Hormone-Positive Breast Cancer Following the Initial Diagnosis of Metastasis
Notice bibliographique
Résumé
Abstract Objectives: Estimate the healthcare costs before and after progression to chemotherapy in a population of post-menopausal hormone-receptor positive (HR+) metastatic breast cancer (mBC) patients. Methods: This retrospective cohort study used claims from a large national US health plan. Females age 55 to 63 were selected if they were diagnosed with metastatic breast cancer between 7/1/01 and 12/31/07, and initiated hormonal therapy before progressing to chemotherapy. Incident metastatic patients were followed until the earliest of disenrollment from the health plan, death, or 12/31/08. The pre-chemotherapy period was defined as the period between the incident diagnosis of metastases and the earlier of the initiation of chemotherapy and the end of the study period. Among the subset of patients with use of chemotherapy, the post-chemotherapy period was defined as the time following chemotherapy initiation until the end of the study. Inflation-adjusted costs were examined during the pre-and post-chemotherapy periods. Descriptive analyses were supplemented with Kaplan-Meier sample-average to adjust for variable follow-up time and censoring. Results: A total of 1,202 patients were identified, 366 (30.4%) of whom progressed to chemotherapy following the onset of metastases. The mean age ± SD was 58.9 ± 2.6 years. On average, patients incurred $79,139 (SD± $121,489) per year in total health care costs before the initiation of chemotherapy and $132,786 (SD± $117,635) after the initiation of chemotherapy. In the pre-chemotherapy and post-chemotherapy phases, medical expenses were $74,149 (SD± $119,838) and $120,942 (SD± $116,225) per patient-year, respectively, while outpatient medications filled at a retail pharmacy or through a mail system pharmacy cost $4,990 (SD± $5033) and $11,843 (SD± $14,431) per patient-year, respectively. On average, most of the observed medical expenses were incurred during outpatient visits with $44,405 (SD± $55,710) and $87,299 (SD± $75,360) per patient-year in the pre-and post-chemotherapy phases respectively. Inpatient stays accounted for $27,147 (SD± $101,405) and $30,118 (SD± $73,216) per patient-year during the pre-and post-chemotherapy periods, respectively. ER visits cost an average of $424 (SD± $1,871) per patient-year during the pre-chemotherapy period and $1,274 (SD± $5,686) per patient-year during the post chemotherapy period, on average. During the post-chemotherapy period, combined costs for both inpatient and outpatient chemotherapy were $33,559 (SD± $38,692) per patient-year on average, and costs for services associated with supportive care for chemotherapy during the same time period accounted for an additional $18,676 (SD± $30,281) per patient-year on average. After adjusting for variable follow-up times, cumulative total healthcare costs were $54,725, $73,107, and $84,200 for years one, two, and three of the pre-chemotherapy period, respectively, and were $92,639, $148,228, and $176,163 during the same portions of the post-chemotherapy period. Conclusions: Post-menopausal HR+ mBC patients incur significant healthcare costs both before and after progressing to chemotherapy. The main cost driver was medical costs in both the pre-and post-chemotherapy periods. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P1-09-02.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,000 | 0,001 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,002 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».